Comparison of triple antithrombotic therapy and dual antiplatelet therapy for patients with atrial fibrillation after percutaneous coronary stenting.
The aim of this study was to evaluate the safety and efficacy of triple antithrombotic therapy with warfarin, aspirin and clopidogrel in patients with atrial fibrillation undergoing percutaneous coronary intervention (PCI). We retrospectively reviewed clinical and follow-up data of 156 consecutive patients with atrial fibrillation after percutaneous coronary stenting. Patients were followed up at 2 and 12 months. A total of 156 consecutive patients were identified. There were 70 patients (dual antiplatelet therapy group, DAPT), warfarin was not used and 86 patients (triple antithrombotic therapy group, TT), both dual antiplatelet therapy and warfarin therapy were prescribed. The baseline data and PCI data were similar in the two groups. The outcome events were similar in the two groups except for bleeding events. There was a significant difference in bleeding risk in the two groups. In summary, triple antithrombotic therapy increases the bleeding risk. Dual antiplatelet therapy decreased this bleeding risk but tended to increase the risk of stroke.